Skip to content
Home
Technology
Pipeline
Our Companies
Leadership
Leadership Voices
News & Events
Join Us
Contact
News & Events
Our latest news
[image placeholder – do not delete]
Select Company
All
Altavant
Enzyvant
Myovant
Spirovant
Sumitovant
Urovant
April 24, 2020
Sumitovant Biopharma Reports Key Clinical and Regulatory Milestones by Myovant Sciences
April 22, 2020
Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
April 21, 2020
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
April 21, 2020
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition
April 14, 2020
Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
March 31, 2020
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
March 10, 2020
Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
March 09, 2020
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
February 25, 2020
Myovant Sciences to Present at Upcoming March Investor Conferences
February 10, 2020
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
« Previous
1
…
3
4
5
6
7
8
Next »